表 1. Clinicopathological characteristics of patients with metastatic prostate cancer (n=41).
转移性前列腺癌患者临床病理特征 （n=41）
| Clinicopathological characteristic | Case (%) or median (P25-P75) |
| mCRPC: metastatic castration-resistant prostate cancer; mHSPC: metastatic hormone-sensitive prostate cancer; PSA: prostate specific antigen; ISUP: International Society of Urological Pathology; ADT: androgen deprivation therapy; NHA: novel endocrine therapy. # Some patients have multiple organ metastases at the same time, such as liver and lung metastases, while others have liver, or lung, or other organ metastases alone. The table is calculated according to one metastatic site, so patients with both liver and lung metastasis are recorded as 1 liver metastasis and 1 lung metastasis, respectively. * Oligometastasis is defined as 1-5 metastases found on PET imaging. Polymetastasis is defined as PET imaging showing more than 5 metastases. | |
| Hormonal status | |
| mCRPC | 26 (63.4) |
| mHSPC | 15 (36.6) |
| Age/yr. | 64 (58-75) |
| PSA level/(ng/mL) | 3.92 (0.51-40.20) |
| <10 | 25 (61.0) |
| ≥10 | 16 (39.0) |
| Gleason score | |
| 7 | 3 (7.3) |
| 8 | 16 (39.0) |
| 9 | 22 (53.7) |
| ISUP/WHO grade | |
| 2 | 1 (2.4) |
| 3 | 2 (4.9) |
| 4 | 16 (39.0) |
| 5 | 22 (53.7) |
| Specific pathological type | |
| Intraductal carcinoma | 6 (14.6) |
| Neuroendocrinization | 7 (17.1) |
| Metastatic sites | |
| Distant lymph nodes | 15 (36.6) |
| Bone | 36 (87.8) |
| Organs# | 9 (22.0) |
| Liver | 4 (9.7) |
| Lung | 6 (14.6) |
| Other organs | 3 (7.3) |
| Local recurrence | 20 (48.8) |
| Metastasis* | |
| Oligometastasis | 20 (48.8) |
| Polymetastasis | 21 (51.2) |
| Previous systemic treatment | |
| Radical surgery±radiotherapy±ADT | 14 (34.1) |
| Radical surgery±radiotherapy±ADT+NHA | 14 (34.1) |
|
Radical surgery±radiotherapy±ADT+other (chemotherapy) |
13 (31.8) |